New Risk • May 18
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Ankündigung • May 14
Epigral Limited, Annual General Meeting, Jun 08, 2026 Epigral Limited, Annual General Meeting, Jun 08, 2026, at 11:00 Indian Standard Time. Reported Earnings • May 05
Full year 2026 earnings released: EPS: ₹76.95 (vs ₹84.68 in FY 2025) Full year 2026 results: EPS: ₹76.95 (down from ₹84.68 in FY 2025). Revenue: ₹25.4b (flat on FY 2025). Net income: ₹3.32b (down 7.2% from FY 2025). Profit margin: 13% (in line with FY 2025). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year. Ankündigung • Apr 29
Epigral Limited to Report Q4, 2026 Results on May 02, 2026 Epigral Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 02, 2026 Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹951, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 25x in the Chemicals industry in India. Negligible returns to shareholders over past three years. Reported Earnings • Jan 31
Third quarter 2026 earnings released: EPS: ₹9.07 (vs ₹24.25 in 3Q 2025) Third quarter 2026 results: EPS: ₹9.07 (down from ₹24.25 in 3Q 2025). Revenue: ₹5.97b (down 7.5% from 3Q 2025). Net income: ₹391.1m (down 62% from 3Q 2025). Profit margin: 6.5% (down from 16% in 3Q 2025). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Ankündigung • Jan 20
Epigral Limited to Report Q3, 2026 Results on Jan 30, 2026 Epigral Limited announced that they will report Q3, 2026 results on Jan 30, 2026 Price Target Changed • Jan 07
Price target decreased by 23% to ₹2,000 Down from ₹2,600, the current price target is provided by 1 analyst. New target price is 73% above last closing price of ₹1,156. Stock is down 37% over the past year. The company posted earnings per share of ₹84.68 last year. Reported Earnings • Nov 11
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: EPS: ₹11.87 (down from ₹19.57 in 2Q 2025). Revenue: ₹5.89b (down 5.9% from 2Q 2025). Net income: ₹512.2m (down 37% from 2Q 2025). Profit margin: 8.7% (down from 13% in 2Q 2025). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year. Ankündigung • Nov 04
Epigral Limited to Report Q2, 2026 Results on Nov 10, 2025 Epigral Limited announced that they will report Q2, 2026 results on Nov 10, 2025 Reported Earnings • Aug 03
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: ₹37.25 (up from ₹20.67 in 1Q 2025). Revenue: ₹6.07b (down 6.9% from 1Q 2025). Net income: ₹1.61b (up 87% from 1Q 2025). Profit margin: 27% (up from 13% in 1Q 2025). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 98%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹2,085, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 43% over the past three years. Ankündigung • Jul 28
Epigral Limited to Report Q1, 2026 Results on Aug 02, 2025 Epigral Limited announced that they will report Q1, 2026 results at 9:08 AM, Indian Standard Time on Aug 02, 2025 Ankündigung • Jun 30
Epigral Limited Approves Final Dividend for the Financial Year Ended 31 March, 2025 Epigral Limited announced that at its AGM held on June 28, 2025, approved payment of Interim Dividend of INR 2.50 (25%) per equity share of INR 10 each and to declare Final Dividend of INR 3.50 (35%) per equity share of INR 10 each fully paid-up for the Financial Year ended 31st March, 2025. Upcoming Dividend • Jun 16
Upcoming dividend of ₹3.50 per share Eligible shareholders must have bought the stock before 20 June 2025. Payment date: 28 July 2025. Payout ratio is a comfortable 7.1% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Reported Earnings • Jun 09
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₹84.68 (up from ₹47.14 in FY 2024). Revenue: ₹25.5b (up 32% from FY 2024). Net income: ₹3.58b (up 83% from FY 2024). Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Declared Dividend • Jun 02
Final dividend of ₹3.50 announced Shareholders will receive a dividend of ₹3.50. Ex-date: 20th June 2025 Payment date: 28th July 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has increased by an average of 18% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 71% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • May 30
Epigral Limited, Annual General Meeting, Jun 28, 2025 Epigral Limited, Annual General Meeting, Jun 28, 2025, at 10:30 Indian Standard Time. Reported Earnings • May 07
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₹84.68 (up from ₹47.14 in FY 2024). Revenue: ₹25.7b (up 33% from FY 2024). Net income: ₹3.58b (up 83% from FY 2024). Profit margin: 14% (up from 10% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Ankündigung • Apr 23
Epigral Limited to Report Q4, 2025 Results on May 05, 2025 Epigral Limited announced that they will report Q4, 2025 results on May 05, 2025 New Risk • Mar 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (64% net debt to equity). Share price has been volatile over the past 3 months (8.1% average weekly change). Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,866, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years. Ankündigung • Feb 28
Epigral Limited Announces Cessation of Bhavin Parikh as an Independent Woman Director The Board of Directors of Epigral Limited vide Circular Resolution, passed on 28th February, 2025, have inter-alia considered and approved cessation of Ms. Nirali Bhavin Parikh as an Independent Woman Director of the Company with effect from close of business hours on 28th February, 2025 pursuant to completion of her second term of five consecutive years. Upcoming Dividend • Jan 31
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 07 February 2025. Payment date: 26 February 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Reported Earnings • Jan 28
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: ₹24.25 (up from ₹11.81 in 3Q 2024). Revenue: ₹6.49b (up 38% from 3Q 2024). Net income: ₹1.04b (up 111% from 3Q 2024). Profit margin: 16% (up from 10% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Ankündigung • Jan 27
Epigral Limited Declares Interim Dividend for the Financial Year 2024-25 Epigral Limited announced at the SBM held on January 27, 2025, the board approved declared interim dividend of INR 2.50 (25%) per Equity Share of face value of INR 10 each for the Financial Year 2024-25 and has fixed 7th February, 2025 as `Record Date' pursuant to regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for ascertaining eligibility of Members for the payment of aforesaid Interim Dividend. Ankündigung • Jan 18
Epigral Limited to Report Q3, 2025 Results on Jan 27, 2025 Epigral Limited announced that they will report Q3, 2025 results on Jan 27, 2025 Reported Earnings • Nov 10
Second quarter 2025 earnings released: EPS: ₹19.57 (vs ₹9.14 in 2Q 2024) Second quarter 2025 results: EPS: ₹19.57 (up from ₹9.14 in 2Q 2024). Revenue: ₹6.32b (up 32% from 2Q 2024). Net income: ₹813.0m (up 114% from 2Q 2024). Profit margin: 13% (up from 7.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Ankündigung • Oct 31
Epigral Limited to Report Q2, 2025 Results on Nov 09, 2024 Epigral Limited announced that they will report Q2, 2025 results at 12:08 PM, Indian Standard Time on Nov 09, 2024 Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹2,296, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 197% over the past three years. New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (77% net debt to equity). Share price has been volatile over the past 3 months (8.7% average weekly change). Reported Earnings • Jul 25
First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024) First quarter 2025 results: EPS: ₹20.67 (up from ₹7.58 in 1Q 2024). Revenue: ₹6.51b (up 43% from 1Q 2024). Net income: ₹858.7m (up 173% from 1Q 2024). Profit margin: 13% (up from 6.9% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in India. Ankündigung • Jul 16
Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024 Epigral Limited announced that they will report Q1, 2025 results on Jul 24, 2024 Ankündigung • Jul 10
Epigral Limited Approves Final Dividend for the Financial Year 2024 Epigral Limited announced that at its Annual General Meeting held on July 9, 2024, approved final dividend of INR 5.00 (50%) per equity share of INR 10 each for the Financial Year 2023-2024. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,559, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 49% over the past year. Upcoming Dividend • Jun 27
Upcoming dividend of ₹5.00 per share Eligible shareholders must have bought the stock before 02 July 2024. Payment date: 08 August 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%). Reported Earnings • Jun 20
Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023) Full year 2024 results: EPS: ₹47.14 (down from ₹85.03 in FY 2023). Revenue: ₹19.3b (down 12% from FY 2023). Net income: ₹1.96b (down 45% from FY 2023). Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue. Declared Dividend • Jun 13
Dividend of ₹5.00 announced Shareholders will receive a dividend of ₹5.00. Ex-date: 2nd July 2024 Payment date: 8th August 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (11% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Jun 13
Epigral Limited, Annual General Meeting, Jul 09, 2024 Epigral Limited, Annual General Meeting, Jul 09, 2024, at 10:30 Indian Standard Time. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Non-Executive Director Kanubhai Patel was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 23
Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023) Full year 2024 results: EPS: ₹47.13 (down from ₹85.03 in FY 2023). Revenue: ₹19.4b (down 12% from FY 2023). Net income: ₹1.96b (down 45% from FY 2023). Profit margin: 10% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue. Ankündigung • Apr 10
Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024 Epigral Limited announced that they will report Q4, 2024 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹1,323, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 38% over the past year. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹1,219, the stock trades at a trailing P/E ratio of 26x. Average forward P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 21% over the past year. Reported Earnings • Jan 26
Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023) Third quarter 2024 results: EPS: ₹11.81 (down from ₹18.58 in 3Q 2023). Revenue: ₹4.72b (down 12% from 3Q 2023). Net income: ₹490.8m (down 36% from 3Q 2023). Profit margin: 10% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Buy Or Sell Opportunity • Jan 25
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 9.0% to ₹998. The fair value is estimated to be ₹812, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Earnings per share has declined by 39%. Ankündigung • Jan 02
Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024 Epigral Limited announced that they will report Q3, 2024 results on Jan 24, 2024 New Risk • Nov 07
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (85% net debt to equity). Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (11% net profit margin). Reported Earnings • Nov 07
Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023) Second quarter 2024 results: EPS: ₹9.14 (down from ₹22.04 in 2Q 2023). Revenue: ₹4.79b (down 14% from 2Q 2023). Net income: ₹380.0m (down 59% from 2Q 2023). Profit margin: 7.9% (down from 17% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Ankündigung • Oct 12
Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023 Epigral Limited announced that they will report Q2, 2024 results on Nov 06, 2023 Reported Earnings • Aug 06
First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023) First quarter 2024 results: EPS: ₹7.58 (down from ₹25.94 in 1Q 2023). Revenue: ₹4.56b (down 14% from 1Q 2023). Net income: ₹315.1m (down 71% from 1Q 2023). Profit margin: 6.9% (down from 20% in 1Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Ankündigung • Jul 29
Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023 Meghmani Finechem Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 05, 2023 Ankündigung • Jun 30
Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023 Meghmani Finechem Limited announced that at its Annual General Meeting held on June 27, 2023, approved final equity dividend at 25% that is INR 2.50 per share on 41,550,158 Equity Shares of INR 10 each for the Financial Year 2022-2023. Upcoming Dividend • Jun 13
Upcoming dividend of ₹2.50 per share at 0.5% yield Eligible shareholders must have bought the stock before 20 June 2023. Payment date: 27 July 2023. Payout ratio is a comfortable 5.9% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%). Recent Insider Transactions • Jun 10
Insider recently bought ₹4.8m worth of stock On the 5th of June, Rameshbhai Patel bought around 5k shares on-market at roughly ₹968 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.8m. Insiders have collectively bought ₹44m more in shares than they have sold in the last 12 months. Ankündigung • Jun 04
Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023 Meghmani Finechem Limited proposed interim dividend paid @25% that is INR 2.50 per share on 4,15,50,158 Equity Shares of INR 10 each fully paid-up, to the shareholders for financial Year 2022- 2023, and to declare final equity Dividend for the financial year 2022-2023. Reported Earnings • Jun 04
Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022) Full year 2023 results: EPS: ₹85.03 (up from ₹60.84 in FY 2022). Revenue: ₹22.0b (up 42% from FY 2022). Net income: ₹3.53b (up 40% from FY 2022). Profit margin: 16% (in line with FY 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Ankündigung • Jun 03
Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023 Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023, at 10:30 Indian Standard Time. Agenda: To receive, consider, and adopt the Audited Standalone Financial Statement of the Company for the Financial Year ended March 31, 2023 together with report of the Board of Directors & Auditors thereon; to receive, consider, and adopt the Audited Consolidated Financial Statement of the Company for the Financial Year ended on March 31, 2023 together with report of the Auditors thereon; to confirm interim dividend payment and to declare Final Equity Dividend for the Financial Year 2022-2023; to appoint a Director in place of Mr. Maulik Patel, who retires by rotation, and being eligible, offers himself for re-appointment; to appoint a Director in place of Mr. Kaushal Soparkar, who retires by rotation, and being eligible, offers himself for re-appointment; and to consider other matters. Recent Insider Transactions • Jun 03
Insider recently bought ₹4.6m worth of stock On the 30th of May, Rameshbhai Patel bought around 5k shares on-market at roughly ₹920 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.8m. Insiders have collectively bought ₹40m more in shares than they have sold in the last 12 months. Reported Earnings • Apr 26
Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022) Full year 2023 results: EPS: ₹85.03 (up from ₹60.84 in FY 2022). Revenue: ₹22.0b (up 42% from FY 2022). Net income: ₹3.53b (up 40% from FY 2022). Profit margin: 16% (in line with FY 2022). Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹962, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 10% over the past year. Recent Insider Transactions • Mar 17
Chairman & MD recently bought ₹4.8m worth of stock On the 14th of March, Maulik Patel bought around 5k shares on-market at roughly ₹968 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹5.1m. Maulik has been a buyer over the last 12 months, purchasing a net total of ₹23m worth in shares. Recent Insider Transactions • Feb 17
Chairman & MD recently bought ₹2.9m worth of stock On the 14th of February, Maulik Patel bought around 3k shares on-market at roughly ₹1,034 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹5.0m. This was Maulik's only on-market trade for the last 12 months. Recent Insider Transactions • Jan 29
Insider recently bought ₹5.0m worth of stock On the 25th of January, Rameshbhai Patel bought around 5k shares on-market at roughly ₹1,044 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹5.8m more in shares than they have sold in the last 12 months. Reported Earnings • Jan 20
Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022) Third quarter 2023 results: EPS: ₹18.68 (down from ₹23.85 in 3Q 2022). Revenue: ₹5.38b (up 7.8% from 3Q 2022). Net income: ₹772.0m (down 22% from 3Q 2022). Profit margin: 14% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Ankündigung • Jan 20
Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023 The Board of Directors of the Meghmani Finechem Limited meeting held on 19 January, 2023 has also declared maiden Interim Dividend at INR 2.50 (i.e. 25%) per Equity Share on 4,15,50,158 Equity Shares of INR 10 each for the year financial year 2022-23. The Interim Dividend will be paid on or after 08 February, 2023. Ankündigung • Jan 12
Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023 Meghmani Finechem Limited announced that they will report Q3, 2023 results on Jan 19, 2023 Reported Earnings • Oct 21
Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022) Second quarter 2023 results: EPS: ₹22.04 (down from ₹23.85 in 2Q 2022). Revenue: ₹5.57b (up 12% from 2Q 2022). Net income: ₹915.7m (down 7.6% from 2Q 2022). Profit margin: 16% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹1,433, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 101% over the past year. Reported Earnings • Jul 22
First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022) First quarter 2023 results: EPS: ₹25.94 (up from ₹7.89 in 1Q 2022). Revenue: ₹5.33b (up 106% from 1Q 2022). Net income: ₹1.08b (up 229% from 1Q 2022). Profit margin: 20% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Ankündigung • Jul 08
Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022 Meghmani Finechem Limited announced that they will report Q1, 2023 results on Jul 21, 2022 Reported Earnings • Jun 05
Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021) Full year 2022 results: EPS: ₹60.84 (up from ₹24.27 in FY 2021). Revenue: ₹15.5b (up 87% from FY 2021). Net income: ₹2.53b (up 151% from FY 2021). Profit margin: 16% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Ankündigung • Jun 04
Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022 Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022, at 10:30 Indian Standard Time. Agenda: To consider the Audited Standalone Financial Statement of the Company for the financial year ended on 31 March, 2022 together with report of the Board of Directors & Auditors thereon; to consider the Audited consolidated Financial Statement of the Company for the financial year ended on 31 March, 2022 together with report of the Board of Directors & Auditors thereon; to consider directorate reappointments; and to consider other matters. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improved over the past week After last week's 16% share price gain to ₹1,398, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 18x in the Chemicals industry in India. Reported Earnings • Apr 27
Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021) Full year 2022 results: EPS: ₹60.84 (up from ₹24.27 in FY 2021). Revenue: ₹15.6b (up 87% from FY 2021). Net income: ₹2.53b (up 151% from FY 2021). Profit margin: 16% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improved over the past week After last week's 16% share price gain to ₹1,170, the stock trades at a trailing P/E ratio of 48.2x. Average trailing P/E is 20x in the Chemicals industry in India. Ankündigung • Apr 05
Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022 Meghmani Finechem Limited announced that they will report fiscal year 2022 results on Apr 25, 2022 Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 20% share price gain to ₹924, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 18x in the Chemicals industry in India. Recent Insider Transactions • Mar 11
CEO, MD & Director recently bought ₹799k worth of stock On the 8th of March, Kaushal Soparkar bought around 1k shares on-market at roughly ₹799 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹7.6m. Kaushal has been a buyer over the last 12 months, purchasing a net total of ₹7.3m worth in shares. Recent Insider Transactions • Dec 17
Insider recently bought ₹762k worth of stock On the 15th of December, Dhiren Goyal bought around 1k shares on-market at roughly ₹762 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹13m. Insiders have collectively bought ₹99m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 20% share price gain to ₹789, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 17x in the Chemicals industry in India. Recent Insider Transactions • Nov 25
Insider recently bought ₹8.3m worth of stock On the 22nd of November, Kalpanaben Patel bought around 12k shares on-market at roughly ₹709 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹13m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Oct 01
Investor sentiment improved over the past week After last week's 21% share price gain to ₹858, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 19x in the Chemicals industry in India. Board Change • Sep 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 13
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 11
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 09
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Sep 07
MD & Additional Director recently bought ₹5.0m worth of stock On the 3rd of September, Kaushal Soparkar bought around 8k shares on-market at roughly ₹662 per share. This was the largest purchase by an insider in the last 3 months. This was Kaushal's only on-market trade for the last 12 months. Board Change • Sep 07
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Additional Director Karana Patel was the last director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
